Drug Trial Radar · NCT04341428
Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
406
Planned (sponsor's estimate)
Start
Jul 2, 2020
Primary completion
Aug 30, 2021
Study completion Dec 30, 2021
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Apr 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.
Conditions
- Healed Erosive Esophagitis
Interventions
DWP14012 20 mgDrug
DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks
DWP14012 20 mg placeboDrug
DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks
Lansoprazole 15 mgDrug
Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
Lansoprazole 15 mg PlaceboDrug
Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 24Time frame: at 24 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea, Yeouido ST. Mary's Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.